Acute Exacerbation of Myasthenia Gravis with Topical Imiquimod Use

Imiquimod activates the immune system when applied to a local area. We report a patient with a history of well-controlled myasthenia gravis who was prescribed imiquimod for lentigo maligna. Treatment was halted after 2 weeks when the patient reported itching and irritating sensations in his throat,...

Full description

Saved in:
Bibliographic Details
Published inProceedings - Baylor University. Medical Center Vol. 30; no. 3; p. 333
Main Authors Saad, Saadeddine, Mansouri, Bobbak, Housewright, Chad
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.07.2017
Taylor & Francis Group LLC
Taylor & Francis Ltd
Baylor Health Care System
Subjects
Antiviral drugs
Care and treatment
Case Studies
Complications and side effects
Development and progression
Dysphagia
Imiquimod
Immune system
Myasthenia gravis
Online AccessGet full text

Cover

More Information
Summary:Imiquimod activates the immune system when applied to a local area. We report a patient with a history of well-controlled myasthenia gravis who was prescribed imiquimod for lentigo maligna. Treatment was halted after 2 weeks when the patient reported itching and irritating sensations in his throat, consistent with previous myasthenia exacerbations. The symptoms improved once imiquimod use was discontinued. We advise clinicians to be cautious when prescribing imiquimod to a patient with a history of myasthenia gravis.
ISSN:0899-8280
1525-3252
DOI:10.1080/08998280.2017.11929637